The Swiss company, which markets Elevidys abroad, said it believes the benefit-risk balance to treatment remains positive in Duchenne patients who can still walk, however.

Douglas E. Williams, Ph.D. Strong track record at executive and board level of building company value across all stages of ...

The abstracts accepted for mini oral presentations include updated efficacy and safety data from the Phase 2b REZILIENT1 ...

Aquestive Therapeutics, Inc. (NASDAQ: AQST) ('Aquestive” or the 'Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science ...

Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement ...

New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025Initial briefing book submitted for review to the European Medicines Agency WARREN, N.J., July 15, 2025 (GLOBE NEW ...

The National Organization for Rare Disorders (NORD®) is honoring a distinguished group of industry leaders and individuals for their contributions to help improve the lives of more than 30 million ...

United Therapeutics Corporation (NASDAQ:UTHR) is among the most undervalued stocks to invest in. It is a biotechnology ...

United Therapeutics (UTHR) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports ...

Roche Holding AG said on Tuesday it has paused all shipments of muscular disorder gene therapy Elevidys outside the U.S., ...

Against that backdrop, United Therapeutics is facing specific questions about near-term sales performance, particularly ...